Black Diamond Therapeutics Inc
Company Profile
Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USAT: +1 617 252-0848
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
Anthropic and OpenAI face commodification threats. Here’s what to watch for
stocks
Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,944.20 | 31.50 | -0.35% |
| CAC 40 | 7,809.66 | 58.39 | -0.74% |
| DAX 40 | 25,117.03 | 202.74 | -0.80% |
| Dow JONES (US) | 51,966.03 | 36.38 | -0.07% |
| FTSE 100 | 10,685.46 | 79.23 | -0.74% |
| HKSE | 23,867.74 | 319.09 | -1.32% |
| NASDAQ | 26,430.89 | 290.85 | 1.11% |
| Nikkei 225 | 64,075.42 | 841.28 | -1.30% |
| NZX 50 Index | 13,631.69 | 20.38 | -0.15% |
| S&P 500 | 7,690.73 | 31.29 | 0.41% |
| S&P/ASX 200 | 8,816.90 | 28.80 | -0.33% |
| SSE Composite Index | 3,735.37 | 4.45 | 0.12% |